OCT system with RNFL and macular databases approved for commercial distribution

Dublin, CA-A new optical coherence tomography (OCT) software application (Cirrus [high-definition] HD-OCT, Carl Zeiss Meditec) has been cleared by the FDA for commercial distribution. The system features retinal nerve fiber layer (RNFL) and macular normative databases and is indicated for in-vivo viewing, axial cross-sectional, and 3-D imaging and measurement of anterior and posterior ocular structures.

“Throughout our 15-year history of OCT innovation, we have seen its utility evolve from imaging of the retina to now offering both posterior and anterior capabilities,” said Michael Kaschke, PhD, president and chief executive officer of Carl Zeiss Meditec. “The [new software] incorporates the latest applications to provide eye care professionals with the tools and analyses needed to manage complex eye conditions throughout a patient’s lifetime.”

The system offers three tools for quantified glaucoma assessment and management:

• The RNFL normative database aims to identify RNFL loss.
• Anterior segment imaging provides visualization of the angle and measurement of central corneal thickness.
• Software (Guided Progression Analysis, Carl Zeiss Meditec) supports glaucoma treatment decision-making by identifying statistically significant changes in RNFL thickness.

To help clinicians better manage retinal diseases and monitor patient response to therapy, the system also offers:

• Macular change analysis to help physicians evaluate retinal status and response to therapy by mapping changes in macular thickness.
• A fovea finder to help identify the center of the fovea to ensure the accuracy of macular thickness measurements.
• Macular thickness normative data to help physicians identify retina disease based on comparison to age-matched data.